Compare Gilead Sciences, Inc. (GILD) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Xpeng Inc - ADR — how do they compare? Gilead Sciences, Inc. trades at $133.43 (market cap $163.51B), while Xpeng Inc - ADR trades at $14.37 (market cap $12.82B). The key difference: Gilead Sciences, Inc. is far larger — about 12.8× Xpeng Inc - ADR's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| GILD | XPEV | |
|---|---|---|
Market Cap | $163.51B | $12.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $28.07 |
52-Week Low | $108.22 | $12.09 |
Enterprise Value | $178.05B | $14.93B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
XPeng (XPEV) trades at $13.36, up 3.17% today, with a bullish technical signal despite mixed earnings. Revenue grew to $76.72B in 2025, but net losses persist at -$1.14B. Analyst consensus is 64.7% buy, supported by strong Q2 2026 deliveries and new model launches. Cash flow improved in 2025, though operational cash flow was negative in 2024.
Outlook is cautiously optimistic with recovery in vehicle sales and global expansion driving potential upside. Key risks include intense EV competition, regulatory pressures, and sustained profitability challenges. The stock's valuation at P/S 1.21 offers growth appeal if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
